BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 23865808)

  • 1. The timing of TGF-β inhibition affects the generation of antigen-specific CD8+ T cells.
    Quatromoni JG; Suzuki E; Okusanya O; Judy BF; Bhojnagarwala P; Venegas O; Eruslanov E; Predina JD; Albelda SM; Singhal S
    BMC Immunol; 2013 Jul; 14():30. PubMed ID: 23865808
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Soluble type II transforming growth factor-beta receptor inhibits established murine malignant mesothelioma tumor growth by augmenting host antitumor immunity.
    Suzuki E; Kapoor V; Cheung HK; Ling LE; DeLong PA; Kaiser LR; Albelda SM
    Clin Cancer Res; 2004 Sep; 10(17):5907-18. PubMed ID: 15355924
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clonal restriction of the expansion of antigen-specific CD8+ memory T cells by transforming growth factor-{beta}.
    Cheng ML; Chen HW; Tsai JP; Lee YP; Shih YC; Chang CM; Ting CC
    J Leukoc Biol; 2006 May; 79(5):1033-42. PubMed ID: 16478921
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The siRNA cocktail targeting interleukin 10 receptor and transforming growth factor-β receptor on dendritic cells potentiates tumour antigen-specific CD8(+) T cell immunity.
    Ahn YH; Hong SO; Kim JH; Noh KH; Song KH; Lee YH; Jeon JH; Kim DW; Seo JH; Kim TW
    Clin Exp Immunol; 2015 Jul; 181(1):164-78. PubMed ID: 25753156
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blockade of transforming growth factor-{beta} signaling in tumor-reactive CD8(+) T cells activates the antitumor immune response cycle.
    Zhang Q; Yang XJ; Kundu SD; Pins M; Javonovic B; Meyer R; Kim SJ; Greenberg NM; Kuzel T; Meagher R; Guo Y; Lee C
    Mol Cancer Ther; 2006 Jul; 5(7):1733-43. PubMed ID: 16891459
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD4+ TH1 cells generated by Ii-PADRE DNA at prime phase are important to induce effectors and memory CD8+ T cells.
    Park JY; Jin DH; Lee CM; Jang MJ; Lee SY; Shin HS; Chung YH; Kim KY; Kim SS; Lee WB; Shin YK; Lee WJ; Park YM; Kim D
    J Immunother; 2010 Jun; 33(5):510-22. PubMed ID: 20463596
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systemic blockade of transforming growth factor-beta signaling augments the efficacy of immunogene therapy.
    Kim S; Buchlis G; Fridlender ZG; Sun J; Kapoor V; Cheng G; Haas A; Cheung HK; Zhang X; Corbley M; Kaiser LR; Ling L; Albelda SM
    Cancer Res; 2008 Dec; 68(24):10247-56. PubMed ID: 19074893
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improving function of cytotoxic T-lymphocytes by transforming growth factor-β inhibitor in oral squamous cell carcinoma.
    Kondo Y; Suzuki S; Takahara T; Ono S; Goto M; Miyabe S; Sugita Y; Ogawa T; Ito H; Satou A; Tsuzuki T; Yoshikawa K; Ueda R; Nagao T
    Cancer Sci; 2021 Oct; 112(10):4037-4049. PubMed ID: 34309966
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human Papilloma Virus Specific Immunogenicity and Dysfunction of CD8
    Krishna S; Ulrich P; Wilson E; Parikh F; Narang P; Yang S; Read AK; Kim-Schulze S; Park JG; Posner M; Wilson Sayres MA; Sikora A; Anderson KS
    Cancer Res; 2018 Nov; 78(21):6159-6170. PubMed ID: 30154146
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transforming Growth Factor β is a Poor Prognostic Factor and Inhibits the Favorable Prognostic Value of CD8+ CTL in Human Hepatocellular Carcinoma.
    Huang CY; Wang H; Liao W; Han F; Li YQ; Chen SW; Lao XM
    J Immunother; 2017 Jun; 40(5):175-186. PubMed ID: 28394813
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced suppression of polyclonal CD8
    Mu C; Zhang X; Wang L; Xu A; Ahmed KA; Pang X; Chibbar R; Freywald A; Huang J; Zhu Y; Xiang J
    J Leukoc Biol; 2017 May; 101(5):1221-1231. PubMed ID: 28096300
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of TGF-β signaling in genetically engineered tumor antigen-reactive T cells significantly enhances tumor treatment efficacy.
    Zhang L; Yu Z; Muranski P; Palmer DC; Restifo NP; Rosenberg SA; Morgan RA
    Gene Ther; 2013 May; 20(5):575-80. PubMed ID: 22972494
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD25 and TGF-β blockade based on predictive integrated immune ratio inhibits tumor growth in pancreatic cancer.
    Pu N; Zhao G; Yin H; Li JA; Nuerxiati A; Wang D; Xu X; Kuang T; Jin D; Lou W; Wu W
    J Transl Med; 2018 Oct; 16(1):294. PubMed ID: 30359281
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term protection against human papillomavirus e7-positive tumor by a single vaccination of adeno-associated virus vectors encoding a fusion protein of inactivated e7 of human papillomavirus 16/18 and heat shock protein 70.
    Zhou L; Zhu T; Ye X; Yang L; Wang B; Liang X; Lu L; Tsao YP; Chen SL; Li J; Xiao X
    Hum Gene Ther; 2010 Jan; 21(1):109-19. PubMed ID: 19715402
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Two Listeria monocytogenes vaccine vectors that express different molecular forms of human papilloma virus-16 (HPV-16) E7 induce qualitatively different T cell immunity that correlates with their ability to induce regression of established tumors immortalized by HPV-16.
    Gunn GR; Zubair A; Peters C; Pan ZK; Wu TC; Paterson Y
    J Immunol; 2001 Dec; 167(11):6471-9. PubMed ID: 11714814
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adoptive transfer of tumor-reactive transforming growth factor-beta-insensitive CD8+ T cells: eradication of autologous mouse prostate cancer.
    Zhang Q; Yang X; Pins M; Javonovic B; Kuzel T; Kim SJ; Parijs LV; Greenberg NM; Liu V; Guo Y; Lee C
    Cancer Res; 2005 Mar; 65(5):1761-9. PubMed ID: 15753372
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antigen-specific cancer immunotherapy using a GM-CSF secreting allogeneic tumor cell-based vaccine.
    Chang EY; Chen CH; Ji H; Wang TL; Hung K; Lee BP; Huang AY; Kurman RJ; Pardoll DM; Wu T
    Int J Cancer; 2000 Jun; 86(5):725-30. PubMed ID: 10797297
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synergistic enhancement of CD8+ T cell-mediated tumor vaccine efficacy by an anti-transforming growth factor-beta monoclonal antibody.
    Terabe M; Ambrosino E; Takaku S; O'Konek JJ; Venzon D; Lonning S; McPherson JM; Berzofsky JA
    Clin Cancer Res; 2009 Nov; 15(21):6560-9. PubMed ID: 19861451
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Truncated form of TGF-βRII, but not its absence, induces memory CD8+ T cell expansion and lymphoproliferative disorder in mice.
    Ishigame H; Mosaheb MM; Sanjabi S; Flavell RA
    J Immunol; 2013 Jun; 190(12):6340-50. PubMed ID: 23686479
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual TGF-β and PD-1 blockade synergistically enhances MAGE-A3-specific CD8
    Chen X; Wang L; Li P; Song M; Qin G; Gao Q; Zhang Z; Yue D; Wang D; Nan S; Qi Y; Li F; Yang L; Huang L; Zhang M; Zhang B; Gao Y; Zhang Y
    Int J Cancer; 2018 Nov; 143(10):2561-2574. PubMed ID: 29981155
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.